See more : Juntendo Co.,Ltd. (9835.T) Income Statement Analysis – Financial Results
Complete financial analysis of Gossamer Bio, Inc. (GOSS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Gossamer Bio, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Boralex Inc. (BRLXF) Income Statement Analysis – Financial Results
- Qing Song Health Co.,Ltd. (6931.TWO) Income Statement Analysis – Financial Results
- Dekel Agri-Vision plc (DKL.L) Income Statement Analysis – Financial Results
- Johnson Chemical Pharmaceutical Works Co., Ltd. (4747.TWO) Income Statement Analysis – Financial Results
- Nocturne Acquisition Corporation (MBTCU) Income Statement Analysis – Financial Results
Gossamer Bio, Inc. (GOSS)
About Gossamer Bio, Inc.
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 4.39M | 4.43M | 5.17M | 4.27M | 3.09M | 297.00K | 0.00 | 0.00 |
| Gross Profit | -4.39M | -4.43M | -5.17M | -4.27M | -3.09M | -297.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 145.30M | 170.92M | 170.27M | 160.85M | 143.40M | 55.28M | 891.00K | 0.00 |
| General & Administrative | 38.46M | 47.61M | 45.78M | 49.73M | 39.14M | 44.05M | 262.00K | 83.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 38.46M | 47.61M | 45.78M | 49.73M | 39.14M | 44.05M | 262.00K | 83.00K |
| Other Expenses | 0.00 | 1.51M | 799.00K | -174.00K | 5.83M | 316.00K | 0.00 | 0.00 |
| Operating Expenses | 183.76M | 218.53M | 216.05M | 210.58M | 182.54M | 99.33M | 1.15M | 83.00K |
| Cost & Expenses | 183.76M | 218.53M | 216.05M | 210.58M | 182.54M | 99.33M | 1.15M | 83.00K |
| Interest Income | 2.00M | 1.58M | 761.00K | 3.44M | 3.63K | 1.72M | 0.00 | 0.00 |
| Interest Expense | 13.51M | 13.88M | 19.44M | 12.67M | 0.00 | 12.00K | 118.00K | 0.00 |
| Depreciation & Amortization | 1.61M | 4.43M | 5.17M | 4.27M | 3.09M | 297.00K | 1.15M | 83.00K |
| EBITDA | -172.15M | -211.07M | -209.32M | -233.96M | -186.14M | -148.99M | -6.65M | -83.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -183.76M | -218.59M | -216.12M | -233.96M | -186.14M | -148.99M | -6.65M | -83.00K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 3.94M | -10.79M | -17.88M | -9.40M | 5.83M | 2.02M | -118.00K | 0.00 |
| Income Before Tax | -179.82M | -229.38M | -234.00M | -243.36M | -180.31M | -146.97M | -6.77M | -83.00K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 10.85M | 15.07M | 8.22M | 511.00K | 2.04M | -5.38M | -83.00K |
| Net Income | -179.82M | -240.23M | -249.08M | -251.58M | -180.82M | -146.97M | -6.77M | -83.00K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.18 | -2.84 | -3.33 | -3.67 | -3.30 | -2.43 | -0.27 | 0.00 |
| EPS Diluted | -1.18 | -2.84 | -3.33 | -3.67 | -3.30 | -2.43 | -0.27 | 0.00 |
| Weighted Avg Shares Out | 152.62M | 84.57M | 74.84M | 68.51M | 54.74M | 60.40M | 24.83M | 24.83M |
| Weighted Avg Shares Out (Dil) | 152.62M | 84.57M | 74.84M | 68.51M | 54.74M | 60.40M | 24.83M | 24.83M |
Gossamer Bio (GOSS) Loses -13.56% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
3 Short Squeeze Penny Stocks To Watch Before 2023
10 Top Penny Stocks To Watch With High Short Interest This Week
Penny Stocks Vs. Blue Chips, 3 Main Differences
Penny Stocks To Buy Now? 6 Short Squeeze Stocks To Watch
Penny Stocks To Buy Now? 3 Short Squeeze Stocks To Watch
Gossamer Bio: Buying The Savage Dip After A Trial 'Win' May Be Unwise
Gossamer Bio tumbles as hypertension drug underperforms rival product in Phase 2 trial
Why Is Gossamer Bio (GOSS) Stock Down Over 70% Today?
Gossamer Bio's stock falls 64% on findings for Phase 2 study for hypertension drug
Source: https://incomestatements.info
Category: Stock Reports